Skip to main content

Table 5 Summary of study design of all orphan medicinal products (n = 59)

From: Clinical evidence for orphan medicinal products-a cause for concern?

  Number of OMPs (%) (n = 59)
Control arm
  At least one study with placebo or standard of care as control 44 (74.6%)
Randomization
  At least one study with random design 46 (78.0%)
Blinding
  At least one study with double blind design 34 (57.6%)